Further studies are needed to address the specific mechanisms underlying TRX2 and ER interaction and potential therapeutic implications, including also the importance of stromal and immune cells in this crosstalk, which will certainly participate in the progression of MASLD disease. Here, TXN2 is linked to metabolic dysfunction-associated steatotic liver disease.